Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6003150 | Thrombosis Research | 2012 | 11 Pages |
Abstract
New anticoagulants promise to have better efficacy, more safety and/or a better manageability than traditional anticoagulants. However, knowledge is limited regarding special situations such as renal insufficiency, obesity, pregnancy, long-term therapy, heparin-induced thrombocytopenia, treatment in patients with mechanical heart valves, use for children, and in patients with a high risk of thromboembolic complications. These situations have rarely or even never been the objective of randomised controlled trials. The purpose of the present article is to summarize and discuss available data on efficacy and safety in these special situations for one of the first new anticoagulants, the indirect factor-Xa inhibitor fondaparinux. Furthermore, we discuss safety in licensed indications and management of bleeding complications and comment on measuring of drug concentration in plasma.
Keywords
FEIBAGFRPF4FFPMDRDrFVIIaUFHVKALMWHINRs.c.VTESVTFDAAnti-factor Xa activityPCCACSEMAAPsSerotonin release assayPulmonary embolismvitamin K antagonistsEuropean Medicines agencyImpaired renal functionU.S. Food and Drug AdministrationHITPregnancyVenous thromboembolismDVTDeep vein thrombosissuperficial vein thrombosisHeparin-induced thrombocytopeniaprothrombin complex concentrateSratwice a daysubcutaneouslyAcute coronary syndromeAntiphospholipid syndromebody mass indexBMIAnti-XaPlatelet factor 4Drug concentrationrecombinant Factor VIIaFondaparinuxGlomerular filtration rateInternational Normalized Ratiounfractionated heparinlow-molecular-weight heparinfresh frozen plasmaBIDChildrenonce daily
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Michael Nagler, Michael Haslauer, Walter A. Wuillemin,